Q3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Reduced by Analyst

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Oramed Pharmaceuticals in a research note issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.04) per share for the quarter, down from their previous forecast of ($0.03). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Oramed Pharmaceuticals’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Oramed Pharmaceuticals’ Q4 2024 earnings at ($0.09) EPS and FY2024 earnings at ($0.10) EPS.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP opened at $2.32 on Wednesday. The firm’s 50 day moving average price is $2.53 and its 200-day moving average price is $2.52. Oramed Pharmaceuticals has a 52-week low of $1.67 and a 52-week high of $4.51. The company has a market cap of $94.26 million, a PE ratio of 8.92 and a beta of 1.87.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.04.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. N.E.W. Advisory Services LLC bought a new position in Oramed Pharmaceuticals during the 3rd quarter valued at about $34,000. Barclays PLC grew its stake in shares of Oramed Pharmaceuticals by 39.0% during the 3rd quarter. Barclays PLC now owns 18,406 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 5,167 shares during the period. Rathbones Group PLC bought a new position in shares of Oramed Pharmaceuticals in the 3rd quarter worth approximately $756,000. Algert Global LLC bought a new stake in Oramed Pharmaceuticals during the third quarter valued at approximately $38,000. Finally, BML Capital Management LLC raised its position in Oramed Pharmaceuticals by 61.5% in the fourth quarter. BML Capital Management LLC now owns 1,261,559 shares of the biotechnology company’s stock worth $2,914,000 after acquiring an additional 480,267 shares during the period. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.